Search

To explore new treatment options – and potentially change the standard of care for resected lung cancer – Memorial Sloan Kettering Cancer Center is enrolling patients in a National Cancer Institute-sponsored trial.

… Friday, September 23, 2016 Memorial Sloan Kettering Cancer Center is proud to be participating in the Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST). ALCHEMIST is a large, multicenter trial sponsored by the National Cancer Institute to assess newly available and

Sloan Kettering Institute Director Thomas J. Kelly has been named a member of the Advisory Committee to the Director (ACD) at the National Institutes of Health.

… Thursday, May 1, 2008 Summary Sloan Kettering Institute Director Thomas J. Kelly has been named a member of the Advisory Committee to the Director (ACD) at the National Institutes of Health. Sloan Kettering Institute Director Thomas J. Kelly has been named a member of the Advisory Committee to the Director

During the early days of the COVID-19 outbreak, a team of radiation oncologists specializing in breast cancer management at Memorial Sloan Kettering Cancer Center reviewed the literature and established recommendations for the safe use of hypofractionated and abbreviated radiation regimens for our patients with breast cancer.

… Monday, May 11, 2020 As governments and health authorities restrict in-person interactions to contain the spread of COVID-19, radiation oncologists must make unprecedented decisions on behalf of patients needing radiotherapy. We must balance the risk of presenting for treatment with being exposed to

Learn about immunotherapy advances for cancer treatment from Dr. Selwyn Vickers, President and CEO of Memorial Sloan Kettering.

… Tuesday, November 7, 2023 Dear MSK Community, Every day we are inspired when our patients are given new hope, thanks to a lifesaving approach to cancer treatment that was pioneered at MSK — immunotherapy . The premise is straightforward: Encourage a person’s own immune system to overpower cancer cells

MSK physicians and scientists are involved in notable research to be presented during the virtual meeting.

… Friday, September 18, 2020 Thousands of oncology experts from around the world will tune in September 19 to 21 for the European Society for Medical Oncology’s (ESMO) Virtual Congress. During the virtual meeting, experts will present promising new developments aimed at improving cancer patient care. This

Doctors from MSK share tips on how to use AI chatbots to get reliable medical information — and explain why you should still rely on your care team to provide advice that is most relevant to you.

… Tuesday, March 17, 2026 If you’ve ever turned to a chatbot to ask questions about your health, you’re in good company. Millions of Americans now go online every day to seek medical advice from chatbots powered by artificial intelligence (AI). People have been Googling their symptoms for decades, but

New MSK research developed CAR T cells that target two acute myeloid leukemia-specific antigens; shed new light on a genetic element called LINE-1, opening the door to new treatments; identified a key regulator of blood stem cell fate; and found an immunotherapy technique using antibodies that target CD47 shows promise in mice.

… Friday, December 29, 2023 New research from Memorial Sloan Kettering Cancer Center (MSK) developed CAR T cells that target two acute myeloid leukemia-specific antigens; shed new light on a genetic element called LINE-1, opening the door to new treatments; identified a key regulator of blood stem cell

Results from a phase 2 clinical trial report a combination of two checkpoint inhibitor immunotherapy drugs given before melanoma surgery prevents this aggressive skin cancer from coming back. This new drug combination also has fewer side effects than other immunotherapy treatments.

… Wednesday, October 26, 2022 When Nancy Schroeder found out her melanoma had spread to her lymph nodes four years after she’d had surgery from a local dermatologist near her home in Florida, she knew she needed to go to Memorial Sloan Kettering Cancer Center (MSK) to benefit from the latest research and

Newly published results from a randomized, Phase III trial show that the drug sunitinib malate (Sutent®) is more effective than the conventional treatment given as an initial therapy for patients with advanced kidney cancer.

… Wednesday, January 10, 2007 Newly published results from a randomized, Phase III trial show that the drug sunitinib malate (Sutent ® ) is more effective than the conventional treatment given as an initial therapy for patients with advanced kidney cancer . The multicenter study, led by Robert Motzer,

In partnership with the Nassau County Department of Health, MSK Nassau will help equitably distribute COVID-19 vaccinations.

… Wednesday, March 10, 2021 As part of MSK’s commitment to support equitable access to COVID-19 vaccines , MSK has partnered with the Nassau County Department of Health to distribute vaccinations to residents from communities disproportionately impacted by the pandemic. The partnership was announced today